Skip to content

Study · Randomized controlled trial · n = 52 · 2022

3 results

Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial.

Kårhus ML, Brønden A, Forman JL, Haaber A, Knudsen E, Langholz E, Dragsted LO, Hansen SH, Krakauer M, Vilsbøll T, Sonne DP, Knop FK

The lancet. Gastroenterology & hepatology20 Jul 2022Cited by 46 (Europe PMC)

PMID35868334 (opens in a new tab)DOI10.1016/s2468-1253(22)00198-4 (opens in a new tab)PepBankPUB-35868334
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with bile acid diarrhoea, more participants on liraglutide (77%) than on colesevelam (50%) had a stool frequency reduction of 25% or more, so liraglutide was superior.

    In plain wordsIn adults with bile acid diarrhoea, more people on liraglutide than on colesevelam had fewer stools.

    Peptide
    Liraglutide
    Outcome
    IncreaseAt least 25% reduction in daily stool frequency at week 6
    Study

    n = 52

    Comparator
    Colesevelam
    Analysis
    Primary
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0·6-1·8 mg per day · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    Responders
    77%
    liraglutide
    Responders
    50%
    colesevelam
    Risk difference
    −27%
    liraglutide vs colesevelam

    Source sentences

    Summary
    20 (77%) of 26 participants on liraglutide and 13 (50%) of 26 on colesevelam experienced a 25% or greater reduction in stool frequency, corresponding to a significant risk difference of -27% in favour of liraglutide (one-sided 95% CI -100 to -6).
    2 context sentences
    Summary · context
    Liraglutide was therefore superior to colesevelam in reducing daily stool frequency.
    Summary · context
    Patients aged 18-75 years with 75selenium-homotaurocholic acid test (SeHCAT)-verified moderate-to-severe primary bile acid diarrhoea were randomly assigned (1:1) to receive liraglutide (one daily subcutaneous injection uptitrated from 0·6-1·8 mg per day over 3 weeks) or colesevelam (three…
  2. 02HumanRandomized controlled trialSafety outcome

    In adults with bile acid diarrhoea, mild nausea lasting 10-21 days was reported by six participants on liraglutide and one on colesevelam.

    In plain wordsIn adults with bile acid diarrhoea, mild nausea was reported by more people on liraglutide than on colesevelam.

    Peptide
    Liraglutide
    Outcome
    IncreaseMild nausea
    Study

    n = 52

    Comparator
    Colesevelam
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0·6-1·8 mg per day · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    Participants with mild nausea
    6 participants
    liraglutide
    Participants with mild nausea
    1 participants
    colesevelam

    Source sentences

    Summary
    Mild nausea with a duration of 10-21 days was reported by six participants in the liraglutide group and by one participant in the colesevelam group.
    1 context sentence
    Summary · context
    Patients aged 18-75 years with 75selenium-homotaurocholic acid test (SeHCAT)-verified moderate-to-severe primary bile acid diarrhoea were randomly assigned (1:1) to receive liraglutide (one daily subcutaneous injection uptitrated from 0·6-1·8 mg per day over 3 weeks) or colesevelam (three…
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with bile acid diarrhoea, no adverse events other than mild nausea were reported.

    In plain wordsIn adults with bile acid diarrhoea, no side effects other than mild nausea were reported.

    Peptide
    Liraglutide
    Outcome
    No significant changeOther adverse events
    Study

    n = 52

    Comparator
    Colesevelam
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0·6-1·8 mg per day · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    No other adverse events were reported.
    1 context sentence
    Summary · context
    Patients aged 18-75 years with 75selenium-homotaurocholic acid test (SeHCAT)-verified moderate-to-severe primary bile acid diarrhoea were randomly assigned (1:1) to receive liraglutide (one daily subcutaneous injection uptitrated from 0·6-1·8 mg per day over 3 weeks) or colesevelam (three…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT07756359

Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

University of North Carolina, Chapel Hilln = 20est. Sept 2026 to est. Sept 2027

Pouch, Ileal · Pouches, Ileoanal · Bowel Diseases, Inflammatory

Trial pageClinicalTrials.govUpdated 10 Aug 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.